Back to research

Research paper

Shared etiology in autism spectrum disorder and epilepsy with functional disability

Review of shared genetic and mechanistic landscape between ASD and epilepsy. Ion channel genes (SCN1A, SCN2A, SCN8A), synaptic scaffolding (SHANK3), and multiple chromatin and mTOR-axis genes are shared. Central shared mechanism is excitation/inhibition imbalance, often via GABAergic dysfunction. Mechanism recognition enables mechanism-aware drug selection.

Indexed context

Zahra A, et al.

autismepilepsyshared-etiologyexcitation-inhibition-balancereview

Markdown path

content/research/papers/2022-zahra-shared-etiology-asd-epilepsy.md

Findings

Review of shared genetic and mechanistic landscape between ASD and epilepsy. Ion channel genes (SCN1A, SCN2A, SCN8A), synaptic scaffolding (SHANK3), and multiple chromatin and mTOR-axis genes are shared. Central shared mechanism is excitation/inhibition imbalance, often via GABAergic dysfunction. Mechanism recognition enables mechanism-aware drug selection.

Why it may matter for Levi

Conceptual scaffold for approaching Levi's ASD-plus-DEE-SWAS as a single-etiology problem. Consistent with Viswanathan 2024 clustering of DEE-SWAS genes into ion-channel/scaffolding and chromatin/transcriptional networks - both networks are high-recurrence in ASD. Reinforces that identifying Levi's underlying lesion is expected to inform both the epilepsy treatment and the ASD developmental trajectory.

Paper text

Zahra et al. (2022) — Shared etiology in ASD and epilepsy

Source

Why this paper is in the corpus

Review of the shared genetic and mechanistic landscape between autism spectrum disorder and epilepsy. Frames the ASD-epilepsy comorbidity not as coincident phenotypes but as downstream manifestations of a common substrate: imbalanced synaptic excitation/inhibition, often driven by GABAergic dysfunction and/or ion-channel or synaptic-scaffolding mutations.

Key findings

  • Genetic crosstalk between ASD and epilepsy includes ion channel genes (SCN1A, SCN2A, SCN8A), synaptic scaffolding proteins (SHANK3), and multiple chromatin and mTOR-axis genes.
  • A central shared mechanism is imbalance between excitatory and inhibitory signaling, often via GABAergic dysfunction.
  • Recognition of shared pathways informs therapeutic decisions: mTOR inhibitors, channel-modulating ASMs, and GABAergic agents can be chosen in a mechanism-aware way rather than empirically.

Levi-relevant takeaways

  • Conceptual scaffold for why Levi's ASD-plus-DEE-SWAS combination should be approached as a single-etiology problem rather than two independent conditions.
  • Consistent with the Viswanathan 2024 observation that DEE-SWAS genes cluster into two functional networks: ion channels/scaffolding/adhesion (SCN1A, SCN2A, SHANK-adjacent) and transcriptional regulators/chromatin modifiers. Both networks are also high-recurrence in ASD.
  • Does not change the current differential but reinforces the principle that identifying Levi's underlying lesion is expected to inform both the epilepsy treatment and the ASD developmental trajectory.

Citation note

Referenced as [28] in the 2026-04-21 user-supplied comprehensive DEE-SWAS / ESES / CSWS research report.